This study is for adults with a type of blood cancer called AML (Acute Myeloid Leukemia) that can't have strong chemotherapy. It looks at a new drug called revumenib to see if it helps when added to two other medicines, azacitidine and venetoclax. Revumenib works by blocking a molecule in cells called menin, which is important for some leukemia cells to grow. The study will focus on patients with specific DNA changes (mutations) known as NPM1 or KMT2A. Participants will be treated until their disease worsens or they have side effects. After treatment, there will be a 4-year follow-up to check overall health and survival.

• Participants need to be at least 18 years old.
• The study will continue until the disease progresses or side effects occur.
• Patients must have specific blood and organ function levels to participate.